DCM
UTHR icon

DGS Capital Management’s United Therapeutics UTHR Stock Holding History

DGS Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$613K Buy
1,034
+193
+23% +$96.1K 0.1% 194
2025
Q4 		$410K Buy
841
+142
+20% +$66.1K 0.07% 242
2025
Q3 		$293K Sell
699
-67
-9% -$22.5K 0.05% 290
2025
Q2 		$220K Buy
+766
New +$229K 0.05% 298

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

DGS Capital Management's UTHR Position: Q1 2026 in Review

DGS Capital Management increased its United Therapeutics (UTHR) stake by 23% in Q1 2026, buying an estimated $96.1K and bringing the position to 1,034 shares worth $613K. The position accounts for 0.1% of the portfolio, ranked #194.

DGS Capital Management first reported a position in UTHR in Q2 2025 and has held it in 4 quarters since. 854 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • DGS Capital Management held 1,034 shares of United Therapeutics worth $613K as of Q1 2026.
  • DGS Capital Management bought 193 United Therapeutics shares in Q1 2026, an estimated $96.1K.
  • United Therapeutics made up 0.1% of DGS Capital Management's portfolio in Q1 2026, its #194 holding.
  • DGS Capital Management first reported a position in United Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 854 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.